1
|
Yao T, Li L. The influence of microbiota on ferroptosis in intestinal diseases. Gut Microbes 2023; 15:2263210. [PMID: 37795964 PMCID: PMC10557621 DOI: 10.1080/19490976.2023.2263210] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Accepted: 09/21/2023] [Indexed: 10/06/2023] Open
Abstract
Ferroptosis is a distinctive form of iron-dependent necrotic cell death, characterized by excessive lipid peroxidation on cellular membranes and compromised cellular antioxidant defenses. Multiple metabolic pathways, including iron and lipid metabolism, as well as antioxidant systems, contribute to the execution of ferroptosis. The gut microbiota exerts regulatory effects on ferroptosis through its microbial composition, biological functions, and metabolites. Notably, most pathogenic bacteria tend to promote ferroptosis, thereby inducing or exacerbating diseases, while most probiotics have been shown to protect against cell death. Given microbiota colonization in the gut, an intimate association is found between intestinal diseases and microbiota. This review consolidates the essential aspects of ferroptotic processes, emphasizing key molecules and delineating the intricate interplay between gut microbiota and ferroptosis. Moreover, this review underscores the potential utility of gut microbiota modulation in regulating ferroptosis for the treatment of intestinal diseases.
Collapse
Affiliation(s)
- Ting Yao
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China
| | - Lanjuan Li
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China
| |
Collapse
|
2
|
Soares JPM, Gonçalves DA, de Sousa RX, Mouro MG, Higa EMS, Sperandio LP, Vitoriano CM, Rosa EBS, dos Santos FO, de Queiroz GN, Yamaguchi RSS, Pereira G, Icimoto MY, de Melo FHM. Disruption of Redox Homeostasis by Alterations in Nitric Oxide Synthase Activity and Tetrahydrobiopterin along with Melanoma Progression. Int J Mol Sci 2022; 23:5979. [PMID: 35682659 PMCID: PMC9181279 DOI: 10.3390/ijms23115979] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Revised: 05/16/2022] [Accepted: 05/20/2022] [Indexed: 12/12/2022] Open
Abstract
Cutaneous melanoma emerges from the malignant transformation of melanocytes and is the most aggressive type of skin cancer. The progression can occur in different stages: radial growth phase (RGP), vertical growth phase (VGP), and metastasis. Reactive oxygen species contribute to all phases of melanomagenesis through the modulation of oncogenic signaling pathways. Tetrahydrobiopterin (BH4) is an important cofactor for NOS coupling, and an uncoupled enzyme is a source of superoxide anion (O2•-) rather than nitric oxide (NO), altering the redox homeostasis and contributing to melanoma progression. In the present work, we showed that the BH4 amount varies between different cell lines corresponding to distinct stages of melanoma progression; however, they all presented higher O2•- levels and lower NO levels compared to melanocytes. Our results showed increased NOS expression in melanoma cells, contributing to NOS uncoupling. BH4 supplementation of RGP cells, and the DAHP treatment of metastatic melanoma cells reduced cell growth. Finally, Western blot analysis indicated that both treatments act on the PI3K/AKT and MAPK pathways of these melanoma cells in different ways. Disruption of cellular redox homeostasis by the altered BH4 concentration can be explored as a therapeutic strategy according to the stage of melanoma.
Collapse
Affiliation(s)
- Jaqueline Pereira Moura Soares
- Department of Physiological Sciences, Santa Casa de São Paulo School of Medical Sciences, São Paulo 01224-001, Brazil; (J.P.M.S.); (R.X.d.S.); (R.S.S.Y.)
| | - Diego Assis Gonçalves
- Department of Parasitology, Microbiology and Immunology, Juiz de Fora Federal University, Juiz de Fora 36036-900, Brazil;
- Micro-Imuno-Parasitology Department, Federal University of Sao Paulo, São Paulo 05508-090, Brazil
| | - Ricardo Xisto de Sousa
- Department of Physiological Sciences, Santa Casa de São Paulo School of Medical Sciences, São Paulo 01224-001, Brazil; (J.P.M.S.); (R.X.d.S.); (R.S.S.Y.)
| | - Margareth Gori Mouro
- Nefrology Discipline, Federal University of Sao Paulo, São Paulo 05508-090, Brazil; (M.G.M.); (E.M.S.H.)
| | - Elisa M. S. Higa
- Nefrology Discipline, Federal University of Sao Paulo, São Paulo 05508-090, Brazil; (M.G.M.); (E.M.S.H.)
| | - Letícia Paulino Sperandio
- Department of Pharmacology, Federal University of Sao Paulo, São Paulo 05508-090, Brazil; (L.P.S.); (G.P.)
| | - Carolina Moraes Vitoriano
- Department of Pharmacology, Institute of Biomedical Science, Universidade de São Paulo, São Paulo 05505-000, Brazil; (C.M.V.); (E.B.S.R.); (F.O.d.S.); (G.N.d.Q.)
| | - Elisa Bachir Santa Rosa
- Department of Pharmacology, Institute of Biomedical Science, Universidade de São Paulo, São Paulo 05505-000, Brazil; (C.M.V.); (E.B.S.R.); (F.O.d.S.); (G.N.d.Q.)
| | - Fernanda Oliveira dos Santos
- Department of Pharmacology, Institute of Biomedical Science, Universidade de São Paulo, São Paulo 05505-000, Brazil; (C.M.V.); (E.B.S.R.); (F.O.d.S.); (G.N.d.Q.)
| | - Gustavo Nery de Queiroz
- Department of Pharmacology, Institute of Biomedical Science, Universidade de São Paulo, São Paulo 05505-000, Brazil; (C.M.V.); (E.B.S.R.); (F.O.d.S.); (G.N.d.Q.)
| | - Roberta Sessa Stilhano Yamaguchi
- Department of Physiological Sciences, Santa Casa de São Paulo School of Medical Sciences, São Paulo 01224-001, Brazil; (J.P.M.S.); (R.X.d.S.); (R.S.S.Y.)
| | - Gustavo Pereira
- Department of Pharmacology, Federal University of Sao Paulo, São Paulo 05508-090, Brazil; (L.P.S.); (G.P.)
| | - Marcelo Yudi Icimoto
- Biophysics Department, Federal University of Sao Paulo, São Paulo 05508-090, Brazil;
| | - Fabiana Henriques Machado de Melo
- Department of Pharmacology, Institute of Biomedical Science, Universidade de São Paulo, São Paulo 05505-000, Brazil; (C.M.V.); (E.B.S.R.); (F.O.d.S.); (G.N.d.Q.)
- Institute of Medical Assistance to Public Servants of the State (IAMSPE), São Paulo 04039-000, Brazil
| |
Collapse
|
3
|
Szadai L, Velasquez E, Szeitz B, de Almeida NP, Domont G, Betancourt LH, Gil J, Marko-Varga M, Oskolas H, Jánosi ÁJ, Boyano-Adánez MDC, Kemény L, Baldetorp B, Malm J, Horvatovich P, Szász AM, Németh IB, Marko-Varga G. Deep Proteomic Analysis on Biobanked Paraffine-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out. Cancers (Basel) 2021; 13:6105. [PMID: 34885218 PMCID: PMC8657028 DOI: 10.3390/cancers13236105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2021] [Revised: 11/24/2021] [Accepted: 11/29/2021] [Indexed: 11/16/2022] Open
Abstract
The discovery of novel protein biomarkers in melanoma is crucial. Our introduction of formalin-fixed paraffin-embedded (FFPE) tumor protocol provides new opportunities to understand the progression of melanoma and open the possibility to screen thousands of FFPE samples deposited in tumor biobanks and available at hospital pathology departments. In our retrospective biobank pilot study, 90 FFPE samples from 77 patients were processed. Protein quantitation was performed by high-resolution mass spectrometry and validated by histopathologic analysis. The global protein expression formed six sample clusters. Proteins such as TRAF6 and ARMC10 were upregulated in clusters with enrichment for shorter survival, and proteins such as AIFI1 were upregulated in clusters with enrichment for longer survival. The cohort's heterogeneity was addressed by comparing primary and metastasis samples, as well comparing clinical stages. Within immunotherapy and targeted therapy subgroups, the upregulation of the VEGFA-VEGFR2 pathway, RNA splicing, increased activity of immune cells, extracellular matrix, and metabolic pathways were positively associated with patient outcome. To summarize, we were able to (i) link global protein expression profiles to survival, and they proved to be an independent prognostic indicator, as well as (ii) identify proteins that are potential predictors of a patient's response to immunotherapy and targeted therapy, suggesting new opportunities for precision medicine developments.
Collapse
Affiliation(s)
- Leticia Szadai
- Department of Dermatology and Allergology, University of Szeged, 6720 Szeged, Hungary; (Á.J.J.); (L.K.); (I.B.N.)
| | - Erika Velasquez
- Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, 205 02 Malmö, Sweden; (E.V.); (J.M.)
| | - Beáta Szeitz
- Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary; (B.S.); (A.M.S.)
| | - Natália Pinto de Almeida
- Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, BMC D13, 221 84 Lund, Sweden; (N.P.d.A.); (M.M.-V.); (G.M.-V.)
- Chemistry Institute Federal, University of Rio de Janeiro, Rio de Janiero 21941-901, Brazil;
| | - Gilberto Domont
- Chemistry Institute Federal, University of Rio de Janeiro, Rio de Janiero 21941-901, Brazil;
| | - Lazaro Hiram Betancourt
- Division of Oncology, Department of Clinical Sciences Lund, Lund University, 221 85 Lund, Sweden; (L.H.B.); (J.G.); (H.O.); (B.B.)
| | - Jeovanis Gil
- Division of Oncology, Department of Clinical Sciences Lund, Lund University, 221 85 Lund, Sweden; (L.H.B.); (J.G.); (H.O.); (B.B.)
| | - Matilda Marko-Varga
- Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, BMC D13, 221 84 Lund, Sweden; (N.P.d.A.); (M.M.-V.); (G.M.-V.)
| | - Henriett Oskolas
- Division of Oncology, Department of Clinical Sciences Lund, Lund University, 221 85 Lund, Sweden; (L.H.B.); (J.G.); (H.O.); (B.B.)
| | - Ágnes Judit Jánosi
- Department of Dermatology and Allergology, University of Szeged, 6720 Szeged, Hungary; (Á.J.J.); (L.K.); (I.B.N.)
| | - Maria del Carmen Boyano-Adánez
- Department of Systems Biology, Faculty of Medicine and Health Sciences, University of Alcala de Henares, 28801 Alcalá de Henares, Madrid, Spain;
| | - Lajos Kemény
- Department of Dermatology and Allergology, University of Szeged, 6720 Szeged, Hungary; (Á.J.J.); (L.K.); (I.B.N.)
- HCEMM-USZ Skin Research Group, University of Szeged, 6720 Szeged, Hungary
| | - Bo Baldetorp
- Division of Oncology, Department of Clinical Sciences Lund, Lund University, 221 85 Lund, Sweden; (L.H.B.); (J.G.); (H.O.); (B.B.)
| | - Johan Malm
- Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, 205 02 Malmö, Sweden; (E.V.); (J.M.)
| | - Peter Horvatovich
- Department of Analytical Biochemistry, Faculty of Science and Engineering, University of Groningen, 9712 CP Groningen, The Netherlands;
| | - A. Marcell Szász
- Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary; (B.S.); (A.M.S.)
- Department of Bioinformatics, Semmelweis University, 1094 Budapest, Hungary
| | - István Balázs Németh
- Department of Dermatology and Allergology, University of Szeged, 6720 Szeged, Hungary; (Á.J.J.); (L.K.); (I.B.N.)
| | - György Marko-Varga
- Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, BMC D13, 221 84 Lund, Sweden; (N.P.d.A.); (M.M.-V.); (G.M.-V.)
- Chemical Genomics Global Research Lab, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea
- Department of Surgery, Tokyo Medical University, Tokyo 160-8402, Japan
| |
Collapse
|